Exécution de notre outil de synthèse sur un nouvel article

Vérifiez l’article ci-dessous, puis lancez sa synthèse.


Nanoparticles-based anti-aging treatment of Alzheimer’s disease

Jianjian Chu (Second Military Medical University, Shanghai Changzheng Hospital), Wenbo Ji (Second Military Medical University, Shanghai Changzheng Hospital), Jianhua Zhuang (Second Military Medical University, Shanghai Changzheng Hospital), Baofeng Gong (Second Military Medical University, Shanghai Changzheng Hospital), Xiaohan Chen (Second Military Medical University, Shanghai Changzheng Hospital), Wenbin Cheng (Second Military Medical University, Shanghai Changzheng Hospital), Wendanqi Liang (Second Military Medical University, Shanghai Changzheng Hospital), Genru Li (Second Military Medical University, Shanghai Changzheng Hospital), Jie Gao (Second Military Medical University, Changhai Hospital), You Yin (Second Military Medical University, Shanghai Changzheng Hospital)

Drug Delivery
Licence : CC BY

Résumé : Age is the strongest risk factor for Alzheimer's disease (AD). In recent years, the relationship between aging and AD has been widely studied, with anti-aging therapeutics as the treatment for AD being one of the mainstream research directions. Therapeutics targeting senescent cells have shown improvement in AD symptoms and cerebral pathological changes, suggesting that anti-aging strategies may be a promising alternative for AD treatment. Nanoparticles represent an excellent approach for efficiently crossing the blood-brain barrier (BBB) to achieve better curative function and fewer side effects. Thereby, nanoparticles-based anti-aging treatment may exert potent anti-AD therapeutic efficacy. This review discusses the relationship between aging and AD and the application and prospect of anti-aging strategies and nanoparticle-based therapeutics in treating AD.

Publié le 19 Jul. 2022